Combination of IGF-1R Targeted Alpha Therapy with Immune Checkpoint Inhibitors Results in Durable Tumour Regression in Colorectal Mouse Model

Time: 11:30 am
day: Day Two


  • Fusion utilizes targeted alpha therapy (TAT) which enables delivery of alpha particle emitting isotopes (actinium 225) to the targeted tumour cells
  • Discussing the rationale for combining TAT with immunotherapy and will give examples of the work we have done in CT26 syngeneic mouse model
  • I will also discuss the mechanism of action behind our therapeutic findings

This talk will be held virtually